CN115212182A - 一种大豆磷脂软胶囊及其制备方法和应用 - Google Patents
一种大豆磷脂软胶囊及其制备方法和应用 Download PDFInfo
- Publication number
- CN115212182A CN115212182A CN202210765848.8A CN202210765848A CN115212182A CN 115212182 A CN115212182 A CN 115212182A CN 202210765848 A CN202210765848 A CN 202210765848A CN 115212182 A CN115212182 A CN 115212182A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- berberine
- lecithin
- soybean lecithin
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 52
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 title claims abstract description 42
- 229940083466 soybean lecithin Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 229920001661 Chitosan Polymers 0.000 claims description 25
- 239000002105 nanoparticle Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000003292 glue Substances 0.000 claims description 18
- 239000000787 lecithin Substances 0.000 claims description 18
- 229940067606 lecithin Drugs 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 13
- 239000008347 soybean phospholipid Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000013871 bee wax Nutrition 0.000 claims description 6
- 239000012166 beeswax Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- FLIBKIRHXYPCJV-UHFFFAOYSA-N ethanol;propan-2-yl tetradecanoate Chemical compound CCO.CCCCCCCCCCCCCC(=O)OC(C)C FLIBKIRHXYPCJV-UHFFFAOYSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 238000007493 shaping process Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002577 cryoprotective agent Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 2
- 229940093265 berberine Drugs 0.000 claims description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 241000233805 Phoenix Species 0.000 abstract 9
- 235000010659 Phoenix dactylifera Nutrition 0.000 abstract 9
- 229940069521 aloe extract Drugs 0.000 abstract 5
- 239000000284 extract Substances 0.000 abstract 5
- 241001116389 Aloe Species 0.000 abstract 4
- 235000011399 aloe vera Nutrition 0.000 abstract 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- 208000008469 Peptic Ulcer Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 208000011906 peptic ulcer disease Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 241000736199 Paeonia Species 0.000 description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种大豆磷脂软胶囊及其制备方法和应用,大豆磷脂软胶囊由芦荟提取物和椰枣籽提取物制备获得,重量比为1:0.6到1:1;通过乙醇萃取芦荟花获得第一芦荟提取物并浓缩;通过乙醇萃取芦荟叶获得第二芦荟提取物并浓缩;通过甲醇萃取椰枣籽得到第一椰枣籽提取物;通过己烷萃取椰枣籽得到第二椰枣籽提取物,混合后蒸发浓缩获得椰枣籽浓缩液;利用第一、第二芦荟提取物和椰枣籽浓缩液制备获得大豆磷脂软胶囊。本发明,通过芦荟提取物和椰枣籽提取物的配伍,利用芦荟抗炎、抗病毒活性的作用,配合椰枣籽抗病毒、抗氧化、抗菌的作用,对治疗消化性溃疡有一定的良好疗效,并且价格低、使用安全。
Description
技术领域
本发明涉及糖尿病药物技术领域,具体涉及一种大豆磷脂软胶囊及其制备方法和应用。
背景技术
大豆磷脂具有降低胆固醇和甘油三脂含量、降低血液粘稠度,防止血液凝固,促进血液循环、促进新陈代谢,减少肝细胞内脂肪的沉积等多种功能。另外,有研究表明,大豆磷脂还可以增强胰脏细胞的功能,降低血糖。因此,配合中药材用于治疗糖尿病。
例如,中国发明专利CN 102599495 B公开了一种牡丹籽油软胶囊及其制备方法,通过以下原料经调和、化胶、胶囊压制成型、硬化定型、洗擦干燥而成,所述份数均为重量份:牡丹籽油80-95份;岩藻甾醇1~3份;角鲨烯1~3份;没食子酸丙酯1~3份;生育酚0.05~0.25份;大豆卵磷脂0.05~0.25份;维生素C0.15~0.25份;明胶5~10份;水5~10份;山梨醇1.3~2.5份;甘油2.5~5份。该方案的主要原料是牡丹籽油,成本高。
有鉴于此,需要研发一种具有治疗糖尿病的大豆磷脂软胶囊,降低原料成本。
发明内容
针对上述缺陷,本发明所要解决的技术问题在于提供一种大豆磷脂软胶囊及其制备方法和应用,以解决现有产品原料成本高的问题。
为此,本发明提供的一种大豆磷脂软胶囊,包括以下重量份数的组分:
氯化小檗碱,10-40;
大豆卵磷脂:100-200;
豆蔻酸异丙酯,40-100;
壳聚糖,10-40。
本发明还提供了一种大豆磷脂软胶囊的制备方法,包括以下步骤:
利用氯化小檗碱、大豆卵磷脂,肉豆蔻酸异丙酯和壳聚糖制备获得小檗碱-卵磷脂纳米颗粒,其中各组分的重量份数据如下:氯化小檗碱,10-40;大豆卵磷脂:100-200;豆蔻酸异丙酯,40-100;壳聚糖,10-40;
配制胶液,具体方法是将300g大豆油和25g蜂蜡加入配料罐中,加热至65-75℃,搅拌30分钟,使蜂蜡完全熔融,降温至40℃±5℃,得油蜡液;再加入小檗碱-卵磷脂纳米颗粒200-300g,搅拌60分钟,置胶体磨中研磨得到料液;
配制胶液,具体方法是取357.9纯化水和150g甘油置化胶罐中,加热至65~75℃后,再加入375g明胶,保温75℃,使明胶溶胶,搅拌约60分钟,直至明胶全部溶解;将化胶罐抽真空,至胶液无气泡;
将上述的胶液和料液投入软胶囊压丸机压制成丸,定型干燥获得大豆磷脂软胶囊;
其中,制备获得小檗碱-卵磷脂纳米颗粒的方法如下:
将肉豆蔻酸异丙酯溶于96%乙醇中,获得肉豆蔻酸异丙酯乙醇溶液,其中肉豆蔻酸异丙酯的含量为1%-3%w/v;
将大豆卵磷脂和氯化小檗碱溶于肉豆蔻酸异丙酯乙醇溶液中,通过10000rpm/min机械搅拌15分钟,超声分散15分钟,配制获得大豆卵磷脂-氯化小檗碱液;
将壳聚糖溶于1%的乙酸水溶液中,得到壳聚糖乙酸液,壳聚糖的含量为1%-3%w/v;
将壳聚糖乙酸液置于磁力搅拌器上,使用注射器将大豆卵磷脂-氯化小檗碱液注入到壳聚糖乙酸液液中,搅拌合成悬浮液;
将悬浮液通过0.45μm过滤膜过滤,在4℃温度下以19000rpm/min离心60分钟,除去上清液;
将沉淀重悬于去离子水中再次在4℃温度下以19000rpm/min离心60分钟离心,重复两次,获得小檗碱-卵磷脂纳米颗粒。
在上述方法中,注射器的注射速率为4mL/min,磁力搅拌器的转速为1000rpm,悬浮液的pH值调整为5.0-5.5。
在上述方法中,小檗碱-卵磷脂纳米颗粒用3%葡萄糖作为冷冻保护剂冻干48小时,并在-20℃下储存直至使用。
在上述方法中,小檗碱-卵磷脂纳米颗粒的粒径为120-230nm,表面电荷为27-36mV。
在上述方法中,软胶囊压丸机转速为2.5~3.0转/分钟,喷体温度为38~48℃,胶皮厚度为0.7mm~0.8mm,调节装量为0.5g/粒,压丸期间保持室温18~26℃,相对湿度45~65%。
在上述方法中,当软胶囊漏油时,将无法擦干净的部分软胶囊经洗丸机,用95%的食用乙醇洗涤,直至软胶囊表面干净。
本发明还提供了一种上述的大豆磷脂软胶囊在制备糖尿病治疗药物或保健品中的应用。
由上述技术方案可知,本发明提供的大豆磷脂软胶囊及其制备方法和应用,通过利用氯化小檗碱、大豆卵磷脂,肉豆蔻酸异丙酯和壳聚糖制备获得小檗碱-卵磷脂纳米颗粒,进而制成大豆磷脂软胶囊,原料成本较低,应用于治疗糖尿病,具有很好的效果。
附图说明
为了更清楚地说明本发明的实施例或现有技术中的技术方案,下面将对本发明实施例或现有技术描述中所需要使用的附图做出简单地介绍和说明。显而易见地,下面描述中的附图仅仅是本发明的部分实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明中大豆磷脂软胶囊制备方法的一种实施例流程图;
图2为大鼠糖尿病治疗实验伤口变化对比照片;
图3为大鼠糖尿病治疗实验伤口闭合百分比对比统计图。
具体实施方式
下面将结合本发明实施例附图,对本发明实施例的技术方案进行清楚、完整地描述,显然,以下所描述的实施例,仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明的实施例,本领域普通技术人员在没有做出创造性劳动的前提下,所获得的所有其他实施例,都属于本发明保护的范围。
为了对本发明的技术方案和实现方式做出更清楚地解释和说明,以下介绍实现本发明技术方案的几个优选的具体实施例。
需要说明的是,本文中“内、外”、“前、后”及“左、右”等方位词是以产品使用状态为基准对象进行的表述,显然,相应方位词的使用对本方案的保护范围并非构成限制。
本发明提供的一种大豆磷脂软胶囊,包括以下重量份数的组分:
氯化小檗碱,10-40;
大豆卵磷脂:100-200;
豆蔻酸异丙酯,40-100;
壳聚糖,10-40。
具体配方实施例请参照以下表1。
表1,大豆磷脂软胶囊有效成分典型配比实施例。
本发明还提供了一种利用上述小檗碱-大豆磷脂-壳聚糖纳米颗粒制备获得大豆磷脂软胶囊的方法,包括以下步骤:
步骤110,制备小檗碱-卵磷脂纳米颗粒。
利用上述配方的氯化小檗碱、大豆卵磷脂,肉豆蔻酸异丙酯和壳聚糖,制备获得小檗碱-卵磷脂纳米颗粒的具体步骤如下:
将肉豆蔻酸异丙酯溶于96%乙醇中,获得肉豆蔻酸异丙酯乙醇溶液,其中肉豆蔻酸异丙酯的含量为1%-3%w/v;
将大豆卵磷脂和氯化小檗碱溶于上述的肉豆蔻酸异丙酯乙醇溶液中,通过10000rpm/min机械搅拌15分钟,超声分散15分钟,配制获得大豆卵磷脂-氯化小檗碱溶液;
将壳聚糖溶于1%的乙酸水溶液中,得到壳聚糖乙酸液,壳聚糖的含量为1%-3%w/v;
将壳聚糖乙酸液溶液置于磁力搅拌器上,使用注射器将大豆卵磷脂-氯化小檗碱液,注入到壳聚糖乙酸液液中,搅拌合成悬浮液。其中,注射器的注射速率为4mL/min,磁力搅拌器的转速为1000rpm。该悬浮液的pH值调整为5.0-5.5。
将悬浮液通过0.45μm过滤膜过滤,在4℃温度下以19000rpm/min离心60分钟,除去上清液;
将沉淀重悬于去离子水中再次在4℃温度下以19000rpm/min离心60分钟离心,重复两次,获得小檗碱-卵磷脂纳米颗粒。小檗碱-卵磷脂纳米颗粒用3%葡萄糖作为冷冻保护剂冻干48小时,并在-20℃下储存直至使用。
经过优化试验,纳米颗粒最佳粒径为168.4nm,表面电荷为33.1mV,该条件下治疗糖尿病的效果最佳。
步骤120,配制料液。
将300g大豆油和25g蜂蜡加入配料罐中,加热至65-75℃,搅拌30分钟,使蜂蜡完全熔融,降温至40℃±5℃,得油蜡液。
加入小檗碱-卵磷脂纳米颗粒200-300g,搅拌60分钟,置胶体磨中研磨得到料液,过80目滤网,置于料液桶中静置4小时左右备用。
步骤130,配制胶液。
取357.9纯化水和150g甘油置化胶罐中,加热至65~75℃后,再加入375g明胶,保温75℃,使明胶溶胶,搅拌约60分钟,直至明胶全部溶解;将化胶罐抽真空,至胶液无气泡。
步骤140,压制成丸。
将上述的胶液和料液投入软胶囊压丸机压制成丸,软胶囊压丸机转速为2.5~3.0转/分钟,喷体温度为38~48℃,胶皮厚度为0.7mm~0.8mm,调节装量为0.5g/粒,压丸期间保持室温18~26℃,相对湿度45~65%。
步骤150,定型干燥。
通过转笼预干机定型,转笼中放上洁净的擦丸布,擦除软胶囊表面的残余石蜡油,第一节和最后一节转笼不放擦丸布;定型完毕的软胶囊送入干燥间干燥,定型时每一节转笼的定型时间不低于15分钟,室温18~26℃,相对湿度45~65%。定型后的软胶囊均匀撒布于洁净的晾丸盘中,每盘厚度以铺平晾丸盘为宜,在干燥间中干燥,干燥温度为21℃~25℃,相对湿度≤45%,干燥40小时左右,使软胶囊胶皮水分含量为9%-13%。
当软胶囊漏油时,需要将无法擦干净的部分软胶囊经洗丸机,用95%的食用乙醇洗涤,直至软胶囊表面干净,在洗丸过程中不得破坏软胶囊的形状。
本发明提供的大豆磷脂软胶囊,可应用于制备糖尿病治疗药物和保健品。
大鼠糖尿病治疗实验如下:
1、实验对象及实验方法。
取170-210克大鼠24只,通过给予链脲佐菌素诱导出糖尿病,随机分为3组,每组8只。
A组,对照组,不使用任何药物;
B组,口服盐酸小檗碱片,剂量0.1克/片;
C组,口服本发明提供的大豆磷脂软胶囊。
链脲佐菌素用后72小时检查糖尿病诱导结果,如果血糖水平超过200mg/dL,并且存在以下症状证实糖尿病诱导成功:多尿、多食和烦渴。每三天检查一次血糖,以确保血糖水平保持稳定。
在糖尿病确认后10天,麻醉大鼠,剃除动物肩胛骨之间的背侧区域,并用70%乙醇消毒,使用直径10mm的无菌活检冲头来形成圆形伤口。
治疗从伤口形成之日(第0天)开始,连续十四天,口服药早、中、晚一日三次,每次一片/粒。
2、结果与评估。
通过宏观观察和伤口闭合百分比对比进行评估。
宏观观察采用的方法是,在第0,3,6,9,12和14天分别拍摄伤口数字图像,在图像上描摹并计算出伤口面积。伤口闭合百分比是指测量天伤口面积与第0天伤口原始面积的比值。
宏观观察结果如图2所示,其中,图片为每组中最有代表性的大鼠伤口照片。
伤口闭合百分比的统计结果如图3所示。
通过图2、图3对比可见,口服盐酸小檗碱片的B组和口服本发明提供的大豆磷脂软胶囊的C组,伤口均得到改善。所有组的伤口一直开放到第九天,口服本发明提供的大豆磷脂软胶囊的C组的伤口在第九天几乎闭合,第14天伤口面积缩小方面表现显著。
综合以上具体实施例的描述,本发明提供的大豆磷脂软胶囊及其制备方法和应用,对糖尿病引起的创伤具有很好的愈合促进作用,并且,原料成本低,有效成分采用纳米颗粒,吸收快,效果好。
最后,还需要说明的是,在本文中使用的术语"包括"、"包含"或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下,由语句"包括一个…"限定的要素,并不排除在包括所述要素的过程、方法、物品或者设备中还存在另外的相同要素。
本发明并不局限于上述最佳实施方式,任何人应该得知在本发明的启示下做出的结构变化,凡是与本发明具有相同或相近的技术方案,均落入本发明的保护范围之内。
Claims (8)
1.一种大豆磷脂软胶囊,其特征在于,包括以下重量份数的组分:
氯化小檗碱,10-40;
大豆卵磷脂:100-200;
豆蔻酸异丙酯,40-100;
壳聚糖,10-40。
2.一种大豆磷脂软胶囊的制备方法,其特征在于,包括以下步骤:
利用氯化小檗碱、大豆卵磷脂,肉豆蔻酸异丙酯和壳聚糖制备获得小檗碱-卵磷脂纳米颗粒,其中各组分的重量份数据如下:氯化小檗碱,10-40;大豆卵磷脂:100-200;豆蔻酸异丙酯,40-100;壳聚糖,10-40;
配制胶液,具体方法是将300g大豆油和25g蜂蜡加入配料罐中,加热至65-75℃,搅拌30分钟,使蜂蜡完全熔融,降温至40℃±5℃,得油蜡液;再加入小檗碱-卵磷脂纳米颗粒200-300g,搅拌60分钟,置胶体磨中研磨得到料液;
配制胶液,具体方法是取357.9纯化水和150g甘油置化胶罐中,加热至65~75℃后,再加入375g明胶,保温75℃,使明胶溶胶,搅拌约60分钟,直至明胶全部溶解;将化胶罐抽真空,至胶液无气泡;
将上述的胶液和料液投入软胶囊压丸机压制成丸,定型干燥获得大豆磷脂软胶囊;
其中,制备获得小檗碱-卵磷脂纳米颗粒的方法如下:
将肉豆蔻酸异丙酯溶于96%乙醇中,获得肉豆蔻酸异丙酯乙醇溶液,其中肉豆蔻酸异丙酯的含量为1%-3%w/v;
将大豆卵磷脂和氯化小檗碱溶于肉豆蔻酸异丙酯乙醇溶液中,通过10000rpm/min机械搅拌15分钟,超声分散15分钟,配制获得大豆卵磷脂-氯化小檗碱液;
将壳聚糖溶于1%的乙酸水溶液中,得到壳聚糖乙酸液,其中,壳聚糖的含量为1%-3%w/v;
将壳聚糖乙酸液置于磁力搅拌器上,使用注射器将大豆卵磷脂-氯化小檗碱液注入到壳聚糖乙酸液液中,搅拌合成悬浮液;
将悬浮液通过0.45μm过滤膜过滤,在4℃温度下以19000rpm/min离心60分钟,除去上清液;
将沉淀重悬于去离子水中再次在4℃温度下以19000rpm/min离心60分钟离心,重复两次,获得小檗碱-卵磷脂纳米颗粒。
3.根据权利要求2所述的方法,其特征在于,注射器的注射速率为4mL/min,磁力搅拌器的转速为1000rpm,悬浮液的pH值调整为5.0-5.5。
4.根据权利要求2所述的方法,其特征在于,小檗碱-卵磷脂纳米颗粒用3%葡萄糖作为冷冻保护剂冻干48小时,并在-20℃下储存直至使用。
5.根据权利要求2所述的方法,其特征在于,小檗碱-卵磷脂纳米颗粒的粒径为120-230nm,表面电荷为27-36mV。
6.根据权利要求2所述的方法,其特征在于,软胶囊压丸机转速为2.5~3.0转/分钟,喷体温度为38~48℃,胶皮厚度为0.7mm~0.8mm,调节装量为0.5g/粒,压丸期间保持室温18~26℃,相对湿度45~65%。
7.根据权利要求2所述的方法,其特征在于,当软胶囊漏油时,将无法擦干净的部分软胶囊经洗丸机,用95%的食用乙醇洗涤,直至软胶囊表面干净。
8.如权利要求1所述的大豆磷脂软胶囊在制备糖尿病治疗药物或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210765848.8A CN115212182A (zh) | 2022-07-01 | 2022-07-01 | 一种大豆磷脂软胶囊及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210765848.8A CN115212182A (zh) | 2022-07-01 | 2022-07-01 | 一种大豆磷脂软胶囊及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115212182A true CN115212182A (zh) | 2022-10-21 |
Family
ID=83610818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210765848.8A Pending CN115212182A (zh) | 2022-07-01 | 2022-07-01 | 一种大豆磷脂软胶囊及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115212182A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958345A (zh) * | 2015-07-14 | 2015-10-07 | 陈雨 | 一种具有降血脂功能的大豆卵磷脂软胶囊及其制备方法 |
CN107308132A (zh) * | 2016-04-26 | 2017-11-03 | 北京五和博澳药业有限公司 | 一种磷脂壳聚糖药物递送***及其制备方法和用途 |
CN108853050A (zh) * | 2018-08-29 | 2018-11-23 | 北京荣祥再生医学研究所有限公司 | 一种药物载体在制备抗糖尿病药物组合物中的应用 |
WO2021090214A2 (en) * | 2019-11-04 | 2021-05-14 | Alesco S.R.L. | Sucrosomial® berberine, its compositions and their use |
US20220273570A1 (en) * | 2019-10-18 | 2022-09-01 | Quicksilver Scientific, Inc. | Self-Microemulsifying Multi-Deliverable Systems |
-
2022
- 2022-07-01 CN CN202210765848.8A patent/CN115212182A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958345A (zh) * | 2015-07-14 | 2015-10-07 | 陈雨 | 一种具有降血脂功能的大豆卵磷脂软胶囊及其制备方法 |
CN107308132A (zh) * | 2016-04-26 | 2017-11-03 | 北京五和博澳药业有限公司 | 一种磷脂壳聚糖药物递送***及其制备方法和用途 |
CN108853050A (zh) * | 2018-08-29 | 2018-11-23 | 北京荣祥再生医学研究所有限公司 | 一种药物载体在制备抗糖尿病药物组合物中的应用 |
US20220273570A1 (en) * | 2019-10-18 | 2022-09-01 | Quicksilver Scientific, Inc. | Self-Microemulsifying Multi-Deliverable Systems |
WO2021090214A2 (en) * | 2019-11-04 | 2021-05-14 | Alesco S.R.L. | Sucrosomial® berberine, its compositions and their use |
Non-Patent Citations (1)
Title |
---|
PANDA DS, 等: "Berberine Encapsulated Lecithin-Chitosan Nanoparticles as Innovative Wound Healing Agent in Type II Diabetes", 《PHARMACEUTICS》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103584081A (zh) | 一种沙棘油微胶囊的制备方法 | |
KR102579754B1 (ko) | 실리빈, ve 및 카르니틴 함유 약학 조성물 | |
CN110559352B (zh) | 一种山楂黄酮微胶囊及其制备方法和应用 | |
CN1171623C (zh) | 治疗肝病的药物的制备方法 | |
CN110151603A (zh) | 一种纳米包裹益母草碱脂质体及其制备方法与应用 | |
CN1278737C (zh) | 一种具有生物活性的复方药物制剂 | |
CN109172537B (zh) | 一种鱼油软胶囊的制备方法 | |
CN108553426B (zh) | 一种壳聚糖滴丸及其制备方法 | |
CN109248257A (zh) | 一种消肿散结的中药制剂及其制备方法 | |
CN115212182A (zh) | 一种大豆磷脂软胶囊及其制备方法和应用 | |
CN102091219A (zh) | 一种新的黄氏响声丸及其制备方法 | |
KR101143363B1 (ko) | 키토산을 이용한 병풀의 면역 증진용 성분의 식용 나노입자 및 그 제조방법, 그 나노입자를 함유한 식품 | |
CN110664785B (zh) | 一种山楂黄酮微胶囊及其制备方法和应用 | |
CN100345534C (zh) | 一种茵栀黄软胶囊及其制备方法和用途 | |
CN1301099C (zh) | 地龙滴丸及其制备方法 | |
CN1292728C (zh) | 复方芦荟微乳组合物及制备方法 | |
CN104523770A (zh) | 一种黑木耳素软胶囊及其制备方法 | |
CN102949587A (zh) | 一种辅助降血糖的复方蜂胶制剂及制备方法 | |
CN112618665B (zh) | 一种提高免疫反应的糠甾醇-谷维素联合用药制剂 | |
CN1506085A (zh) | 黄连上清软胶囊剂及其制备工艺 | |
CN107348505A (zh) | 含有金花茶、螺旋藻、低聚果糖的功能食品的制作方法 | |
CN1431016A (zh) | 调节血糖、血脂保健食品的组成及其制备方法 | |
CN1836680A (zh) | 复方三七总皂苷葛根素制剂 | |
KR0128493B1 (ko) | 장원 연질캅셀의 제조방법 | |
CN1682821A (zh) | 复方半边莲滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221021 |